PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 September; 7(3): E114–E125.
Published online 2006 September 1. doi:  10.1208/pt070371
PMCID: PMC2750513
NIHMSID: NIHMS224164

Chemical stabilization of a Δ9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: Role of microenvironment pH

Abstract

This research was conducted in order to fabricate stable polyethylene oxide (PEO)-based transmucosal systems of a Δ9-tetrahydrocannabinol (THC) prodrug, a hemisuccinate ester, using a hot-melt method. Since Δ9-tetrahydrocannabinol (THC-HS) was heat labile, a series of processing aids were evaluated in order to facilitate hot-melt production at lower temperatures, thereby reducing THC-HS degradation. The stability of THC-HS was influenced both by the processing conditions such as heating time and temperature, and the postprocessing storage conditions. The type of formulation additive also affected the extent of degradation. In the presence of polyethylene glycol (PEG)-400, the percentage of relative degradation of THC-HS to THC was 13.5% and 49.4% at 80°C and 120°C, respectively. In contrast, incorporation of vitamin E succinate (VES) reduced processing degradation to 2.1% and 9.2%, respectively, under the same conditions. Severe degradation of THC-HS was observed during storage, even under freezing conditions (−18°C). A VES-Noveon AA-1 combination was observed to best stabilize the prodrug systems both during processing and postprocessing. Stabilization of THC-HS was achieved in these polyethylene oxide matrices at 4°C, with almost 90% of theoretical drug remaining for up to 8 months. Investigation of the pH effect revealed that the pH of the microenvironment in these polymeric systems could be modulated to significantly improve the stability of THC-HS, degradation being the least in a relatively acidic medium.

Keywords: chemical degradation, hot-melt, pH microenvironment, plasticizers, polyethylene oxide, polymer, prodrug, Δ9-tetrahydrocannabinol

Full Text

The Full Text of this article is available as a PDF (503K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Munjal M, Repka MA. Chemical stabilization of an unstable tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method [abstract].AAPS J [serial online]. 2004; Abstract R6085. [PMC free article]
2. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126:791–798. [PubMed]
3. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409–416. [PubMed]
4. Doyle E, Spence AA. Cannabis as a medicine? Br J Anaesth. 1995;74:359–361. doi: 10.1093/bja/74.2.241. [PubMed] [Cross Ref]
5. Agurell S, Halldin M, Lindgren J, et al. Pharmacokinetics and metabolism of Δ-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21–34. [PubMed]
6. Pop E. Nonpsychotropic synthetic cannabinoids. Curr Pharm Des. 2000;6:1347–1359. doi: 10.2174/1381612003399446. [PubMed] [Cross Ref]
7. ElSohly MA, Stanford DF, Harland EC, et al. Rectal bioavailability of Δ-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci. 1991;80:942–945. doi: 10.1002/jps.2600801008. [PubMed] [Cross Ref]
8. ElSohly MA, Little TLJ, Hikal A, Harland E, Stanford DF, Walker L. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav. 1991;40:497–502. doi: 10.1016/0091-3057(91)90353-4. [PubMed] [Cross Ref]
9. Perlin E, Smith CG, Nichols AI, et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the Rhesus monkey. J Pharm Sci. 1985;74:171–174. doi: 10.1002/jps.2600740213. [PubMed] [Cross Ref]
10. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, Elsohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav. 1993;44:745–747. doi: 10.1016/0091-3057(93)90194-X. [PubMed] [Cross Ref]
11. Silva BO, Cleary RW, ElSohly MA, Jones AB, Kibbe AH. Kinetic study of the hydrolysis of Δ9-tetrahydrocannabinol hemisuccinate in semi-aqueous solvents. Arch Pharm Chem (Kbh). 1985;13:53–57.
12. ElSohly MA, inventor. University of Mississippi, assignee. Stable suppository formulations effecting bioavailability of Δ9-THC. US patent 5 389 375. May 21, 1993.
13. Zhang F, McGinity JW. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharm Dev Technol. 1999;4:241–250. doi: 10.1081/PDT-100101358. [PubMed] [Cross Ref]
14. Repka MA, Gutta K, Prodduturi S, Munjal M, Stodghill SP. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur J Pharm Biopharm. 2005;59:189–196. doi: 10.1016/j.ejpb.2004.06.008. [PubMed] [Cross Ref]
15. Repka MA, Gerding TG, Repka SL, McGinity JW. Influence of plasticizers and drugs on the physical-mechanical properties of hydroxy-propylcellulose films prepared by hot-melt extrusion. Drug Dev Ind Pharm. 1999;25:625–633. doi: 10.1081/DDC-100102218. [PubMed] [Cross Ref]
16. Crowley MM, Zhang F, Koleng JJ, McGinity JW. Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials. 2002;23:4241–4248. doi: 10.1016/S0142-9612(02)00187-4. [PubMed] [Cross Ref]
17. Munjal M, Stodghill SP, ElSohly MA, Repka MA. Polymeric systems for amorphous Δ9-tetrahydrocannabinol produced by a hot-melt method. I. Chemical and thermal stability during processing.J Pharm Sci. In press. [PubMed]
18. Heng PWS, Chan LW, Ong KT. Influence of storage conditions and type of plasticizers on ethylcellulose and acrylate films formed from aqueous dispersions. J Pharm Pharm Sci. 2003;6:334–344. [PubMed]
19. Banker GS. Film coating theory and practice. J Pharm Sci. 1966;55:81–89. doi: 10.1002/jps.2600550118. [PubMed] [Cross Ref]
20. Morflex Inc. The role of plasticizers as functional excipients in harmaceutical dosage forms prepared by hot-melt extrusion [Pharmaceutical Coatings Bulletin 102-6]. 2004. Greensboro, NC: Morflex Inc. Available at: http://www.morflex.com/pdf/Bul102.6.pdf. Accessed: May 30, 2006.
21. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci. 2005;94:2463–2474. doi: 10.1002/jps.20385. [PubMed] [Cross Ref]
22. Mendenhall DW. Stability of parenterals. Drug Dev Ind Pharm. 1984;10:1297–1342. doi: 10.3109/03639048409039056. [Cross Ref]
23. Strickley RG, Visor GC, Lin L, Gu L. An unexpected pH effect on the stability of moexipril lyophilized powder. Pharm Res. 1989;6:971–975. doi: 10.1023/A:1015901731275. [PubMed] [Cross Ref]
24. Carstensen JT, Kothari RC. Solid-state decomposition of alkoxyfuroic acids in the presence of microcrystalline cellulose. J Pharm Sci. 1983;72:1149–1154. doi: 10.1002/jps.2600721010. [PubMed] [Cross Ref]
25. Usui F, Carstensen JT. Interactions in the solid state. I. Interactions of sodium bicarbonate and tartaric acid under compressed conditions. J Pharm Sci. 1985;74:1293–1297. doi: 10.1002/jps.2600741209. [PubMed] [Cross Ref]
26. Badawy SI, Williams RC, Gilbert DL. Chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. J Pharm Sci. 1999;88:428–433. doi: 10.1021/js9803297. [PubMed] [Cross Ref]
27. Badawy SIF, Williams RC, Gilbert DL. Effect of different acids on solid-state stability of an ester prodrug of a IIb/IIIa glycoprotein receptor antagonist. Pharm Dev Technol. 1999;4:325–331. doi: 10.1081/PDT-100101368. [PubMed] [Cross Ref]
28. Hsu CH, Jay M, Bummer PM, Lehmler HJ. Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation. Pharm Res. 2003;20:918–925. doi: 10.1023/A:1023899505837. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists